In the last trading session, 1.68 million shares of the Aldeyra Therapeutics Inc (NASDAQ:ALDX) were traded, and its beta was 1.17. Most recently the company’s share price was $1.91, and it changed around $0.02 or 1.06% from the last close, which brings the market valuation of the company to $114.05M. ALDX currently trades at a discount to its 52-week high of $7.20, offering almost -276.96% off that amount. The share price’s 52-week low was $1.14, which indicates that the current value has risen by an impressive 40.31% since then. We note from Aldeyra Therapeutics Inc’s average daily trading volume that its 10-day average is 5.72 million shares, with the 3-month average coming to 1.35 million.
Aldeyra Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended ALDX as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. Aldeyra Therapeutics Inc is expected to report earnings per share of -0.24 for the current quarter.
Aldeyra Therapeutics Inc (NASDAQ:ALDX) trade information
Instantly ALDX has showed a green trend with a performance of 1.06% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 2.3200 on recent trading dayincreased the stock’s daily price by 17.67%. The company’s shares are currently down -61.72% year-to-date, but still up 1.06% over the last five days. On the other hand, Aldeyra Therapeutics Inc (NASDAQ:ALDX) is -71.95% down in the 30-day period. We can see from the shorts that 3.55 million shares have been sold at a short interest cover period of 3.87 day(s).
The consensus price target as assigned by Wall Street analysts is $11, which translates to bulls needing to increase their stock price by 82.64% from its current value. Analyst projections state that ALDX is forecast to be at a low of $10 and a high of $12.
Consensus estimates provided by 6 financial analysts predict the company will bring in an average of -666.67k in revenue for the current quarter. 6 analysts expect Aldeyra Therapeutics Inc to make 30M in revenue for the current ending quarter. Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 15.99%.
ALDX Dividends
Aldeyra Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-Feb-27.
Aldeyra Therapeutics Inc (NASDAQ:ALDX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 2.43% of Aldeyra Therapeutics Inc shares, and 55.77% of them are in the hands of institutional investors. The stock currently has a share float of 57.16%. Aldeyra Therapeutics Inc stock is held by 160.0 institutions, with PERCEPTIVE ADVISORS LLC being the largest institutional investor. By 2024-06-30, it held 15.6121% of the shares, which is about 9.28 million shares worth $30.7 million.
KNOLL CAPITAL MANAGEMENT, LLC, with 9.2158% or 5.48 million shares worth $18.12 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF were the top two Mutual Funds as of Dec 31, 2024 . The former held 1.76 shares worth $3.36 million, making up 2.95% of all outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held roughly 1.29 shares worth around $2.47 million, which represents about 2.16% of the total shares outstanding.
